Exhibit 10.3**AMENDMENT TO EMPLOYMENT AGREEMENT**This Amendment to Employment Agreement is dated as of May 1, 2008 (the “Amendment”) by and betweenPerrigo Company (the “Parent”), Perrigo Israel Pharmaceuticals, Ltd., formerly Agis Industries(1983) Ltd. (the “Company”), and Refael Lebel (the “Executive”).     WHEREAS the Parent, Company and Executive are parties to a certain Employment Agreement datedas of November 14, 2004 (the “Employment Agreement”) which provides, among other things, that theCompany agrees to employ the Executive subject to certain terms and conditions contained in theEmployment Agreement; and     WHEREAS the Parent, Company and Executive wish to amend the Employment Agreement as set forthherein.     NOW THEREFORE, in consideration of the mutual covenants and agreements set forth below and forother good and valuable consideration, the receipt and sufficiency of which are acknowledged, theparties agree as follows:     **1. ****Amendment****.** a. Section 1(a) of the Employment Agreement is deleted in itsentirety and replaced by the following:    “Subject to the terms of this Agreement, the Company agrees to employ theExecutive in the position of President during the Agreement Term (as definedin Section 1(i) below), and the Executive agrees to remain in the employ ofthe Company during the Agreement Term. The Parent agrees to appoint theExecutive and the Executive agrees to serve, as an Executive Vice Presidentand as a member of the Parent’s Executive Committee (“Executive Committee”).”  b. Section 1(c) of the Employment Agreement is deleted in itsentirety and replaced by the following:    “The Executive shall report to the Parent’s Chief Executive Officer and shallperform such duties as may be assigned to him by the Chief Executive Officer.Such duties shall include daily leadership and coordination of the Parent’sand Company’s (1) generic pharmaceuticals business outside North America, (2)global API business, (3) the Israel-based Consumer Products and Pharmaceuticaland Diagnostics businesses, and (4) the Israel-based pharmaceuticals’operations, including monitoring achievement of operations and financialresults and developing growth strategies to achieve ongoing
1

 
   objectives. Current Company staff (except those in the United States), shalldirectly report to the Executive. The Parent may make changes to theExecutive’s position, title, reporting line, authority and responsibilities,provided that the totality of the Executive’s position, title, reporting line,authority and responsibilities as comparable to those typically attributableto members of the Executive Committee.”  c. The first sentence of Section 1(i) is deleted in its entiretyand replaced by the following:   “This Agreement shall govern the terms and conditions of theExecutive’s employment and any termination thereof from the EffectiveDate until March 17, 2011 (the “Agreement Term”).” d. Section 2(a) of the Employment Agreement is deleted in itsentirety and replaced by the following:    “Base Salary. The Executive shall receive base salary at an annual rate of1.670.000 NIS, payable in substantially equal monthly or more frequentinstallments (the “Salary”). Commencing on or around October 2008, theExecutive’s Salary shall be reviewed for increase at least annually by theChief Executive Officer, the Board or the Compensation Committee of the Boardpursuant to the normal review process for members of the Executive Committee.Any increase in Salary shall not serve to limit or reduce any other obligationto the Executive under this Agreement.”  e. The third sentence of Section 2(b) of the EmploymentAgreement is deleted in its entirety and replaced by the following:    “The MIB shall provide the Executive with a target bonus opportunity of 60% ofannual salary for each fiscal year of the Parent.”  f. Section 3(g)(i) is deleted in its entirety and replaced bythe following:   “. . . (i) any breach or violation of Section 1(c) or the Parent orCompany requiring the Executive to relocate his principal place ofemployment outside the State of Israel, . . .” g. Section 7 of the Employment Agreement is deleted in itsentirety.
2

 
 **2.** **Confidentiality and Noncompetition****.**    In consideration for the payments and benefits contemplated by Section 4 of theEmployment Agreement, the Executive acknowledges and agrees that simultaneous with theexecution of this Amendment, he will be required to execute and comply with theNoncompetition and Nondisclosure Agreement in the form attached to this Amendment asExhibit A. This Noncompetition and Nondisclosure Agreement supersedes and replaces theprevious Noncompetition and Nondisclosure Agreement entered into on November 14, 2004by and between the Parent and Executive.  **3.** **Effect of Amendment****.**    Except to the extent expressly amended hereby, the Employment Agreement shall remain infull force and effect in all respects.  **4.** **Applicable Law****.**    This Amendment shall be governed by and construed and enforced in accordance with theinternal laws of the State of Israel without regard to principles of conflict of laws.Any proceeding related to or arising out of this Amendment shall be commenced,prosecuted or continued in Israel. Notwithstanding the foregoing, any controversyrelating to provisions of Section 2(b) and 2(c) of the Employment Agreement shall begoverned by the laws of the jurisdiction set forth in the applicable award document.  **5.** **Counterparts****.**    This amendment may be executed in one or more counterparts (including counterpartsexecuted and delivered by facsimile, which shall be as counterparts executed anddelivered manually) all of which shall be considered one in the same agreement andshall become effective when one or more counterparts have been signed by each of theparties and delivered to the other parties as being understood that all parties do notsign the same counterpart.
3

 
IN WITNESS WHEREOF, this Amendment has been duly executed by the parties as of the day and yearfirst written above.PERRIGO COMPANY     By: /s/ Joseph C. Papa       Its: President and Chief Executive Officer  EXECUTIVE     By: /s/ Refael Lebel   PERRIGO ISRAEL PHARMACEUTICALS LTD.     By: /s/ Judy L. Brown       Its: Executive Vice President and